Biotech VC Funds

LongeVC is a venture capital firm specializing in early-stage investments in biotechnology, with a strong focus on longevity and age-related innovations. Based in Lugano, Switzerland, and Latvia, the firm targets breakthrough startups in sectors like biotech, life sciences, and therapeutics that aim to extend human health and longevity. LongeVC typically invests between €0.5 million and €2.3 million in companies across Europe, the U.S., and Israel. The firm is backed by a deep scientific advisory board and meticulously prioritizes scientific due diligence. Their portfolio includes leading biotech startups such as Insilico Medicine, known for AI-driven drug discovery, and Longenesis, which provides tools for collaborative biotech research. LongeVC's mission is to bring life-changing health technologies to market, addressing global challenges like aging and healthcare. Led by partners like Ilya Suharenko and Garri Zmudze, LongeVC offers not only capital but also strategic business development support, helping founders build scalable businesses that can make a global impact.

Longevity Vision Fund (LVF) is a venture capital firm based in New York City, founded by Sergey Young. The fund focuses on investing in technologies and companies that aim to extend healthy human lifespans and address the negative effects of aging. With a $100 million fund, LVF supports innovations in preventive medicine, early detection, medical technologies, artificial intelligence in healthcare, longevity therapies, and regenerative medicine. LVF's mission is to accelerate breakthroughs in longevity and make these advancements more accessible and affordable to the general public. Notable investments include Senda Biosciences, a company dedicated to developing treatments through its proprietary molecular platform. The fund is led by Sergey Young, a prominent figure in the longevity space with over 20 years of investment experience. Other key team members include Avetik Arakelyan, Sourav Sinha, and Kris Verburgh, who bring diverse expertise in healthcare, technology, and finance. LVF targets early-stage investments and partners with innovative companies worldwide, aiming to transform the life sciences and healthcare industries. They emphasize a long-term commitment to improving human health and promoting a healthier, longer life for everyone.

Longitude Capital is a healthcare-focused venture capital firm that invests across biotechnology, medical technology, and health solutions sectors. Established in 2006, the firm seeks out transformative companies that can improve clinical outcomes, enhance quality of life, and drive healthcare efficiencies. They invest across various stages, from startups to growth companies, with a unique focus on areas like oncology, neurodegenerative diseases, aging, and cardiovascular solutions. Longitude's approach is flexible, allowing them to invest in early clinical-stage companies, spin-outs, and even publicly traded firms. The firm is known for its involvement in special situations, including recapitalizations and PIPEs (Private Investment in Public Equity). They have a proven track record with successful IPOs and acquisitions, such as Aimmune Therapeutics, KaNDy Therapeutics, and Axonics Modulation Technologies. With $585 million raised in its latest fund (LVP4), Longitude Capital's strategy remains rooted in long-term value creation, bolstered by robust internal research teams. Their offices are located in Menlo Park, Greenwich, and Boston, and they continue to partner with both emerging and established healthcare innovators.

Longwall Ventures is a UK-based venture capital firm specializing in early-stage investments in the health, resilience, and sustainability sectors. Founded with a mission to support innovative startups, Longwall Ventures has a strong focus on companies that leverage science and engineering to create impactful solutions. Notable investments by Longwall Ventures include Wayland Additive, which develops advanced 3D printing technologies; Lightcast Discovery, a biotechnology firm; and Caristo Diagnostics, which focuses on cardiovascular diagnostics. The firm has also invested in Closed Loop Medicine, a company developing personalized drug and digital therapy combinations, and LettUs Grow, which specializes in vertical farming technology. Longwall Ventures is known for its hands-on approach, providing not only capital but also strategic support to its portfolio companies. With a diverse portfolio of over 40 companies, Longwall Ventures continues to play a crucial role in fostering innovation and supporting the growth of early-stage companies in the UK and beyond.

Longwood Fund, founded in 2010 and based in Boston, Massachusetts, is a venture capital firm specializing in creating and investing in science-based companies that develop novel solutions to address important medical needs. The fund's principals have co-founded 25 companies, serving as CEOs, Chief Business Officers, and lead investors, and have helped advance over 20 products to market. Longwood Fund's portfolio includes several notable companies such as Grail, which focuses on early cancer detection, and TScan Therapeutics, which develops novel T cell therapies for cancer. Other significant investments include Immunitas Therapeutics, a company using single-cell genomics to innovate in immune oncology, and Be Biopharma, which is developing engineered B cells as a new category of cellular medicines. The fund emphasizes a value-add investment approach, actively supporting its portfolio companies in accelerating clinical progress from lab to patient. With a strong track record of successful exits, including Pyxis Oncology and PTC Therapeutics, Longwood Fund continues to play a pivotal role in advancing healthcare innovations.

Lonza is a global leader in the life sciences industry, providing contract development and manufacturing services (CDMO) for the pharmaceutical, biotech, and nutrition sectors. With headquarters in Basel, Switzerland, Lonza operates over 50 sites worldwide, offering end-to-end solutions across biologics, small molecules, cell and gene therapies, and more. In addition to its CDMO services, Lonza is deeply involved in venture capital through strategic partnerships and investments. The company collaborates with venture capital firms like ALSA Ventures and Bioqube Ventures to support emerging biotech startups, focusing on developing innovative therapies. Lonza's role in these partnerships often includes early-stage de-risking, development, and manufacturing services, helping startups navigate the complexities of bringing new treatments to market. Lonza has also launched a venture capital fund with Prolog Ventures to invest in North American health and wellness startups. This fund is part of Lonza's broader strategy to foster innovation in the health sector by supporting companies that align with its mission to improve patient outcomes and address unmet medical needs​.

Look Up Ventures is a Copenhagen-based venture capital firm focused on early-stage investments that address climate emergencies and biodiversity loss. Founded by Tommy Ahlers and Nicolaj Reffstrup, the firm backs pragmatic and systemic solutions in sectors like materials, energy, food and agriculture, transport, and carbon management. Their portfolio includes companies like Sirona Technologies, which develops CO2 capture technology, and Rubi, which creates carbon-negative textiles using synthetic biology. Look Up Ventures typically invests between €1.5 million and €3 million in pre-seed to Series A rounds. The team, consisting of experienced founders and operators, provides not just capital but also strategic support, helping startups with scaling, team building, and impact performance. Recent investments include companies such as Arkeon, which turns CO2 into food ingredients, and Ento Labs, which uses AI to optimize energy consumption. The firm operates primarily across Europe and aims to make meaningful contributions to reversing climate change by supporting scalable, science-based innovations.

Lool Ventures is a Tel Aviv-based early-stage venture capital firm that invests primarily in Israeli startups. Founded in 2012, the firm focuses on seed and pre-seed funding, helping ambitious entrepreneurs build innovative companies that can compete on a global scale. Lool Ventures is sector-agnostic, with investments spanning across areas such as fintech, digital health, SaaS, AI, logistics, and more, demonstrating a commitment to backing technology that transforms industries. The firm is known for its hands-on approach, partnering closely with startups to provide not just capital but also strategic guidance, mentorship, and operational support. Lool Ventures typically leads or co-leads investment rounds, and its involvement often extends from the earliest stages through Series A. The firm’s diverse portfolio includes companies like Bringg, a leading logistics platform; CyberMDX, which focuses on healthcare cybersecurity; and Zencity, a data analytics platform for local governments. Lool Ventures’ team, led by General Partners Avichay Nissenbaum and Yaniv Golan, brings a wealth of entrepreneurial experience, which helps them connect with founders and anticipate the challenges faced during the growth phase. With assets under management totaling around $200 million, Lool Ventures continues to play a significant role in Israel’s startup ecosystem, seeking out visionary founders who are ready to innovate and disrupt traditional markets.

Loup Ventures is a Minneapolis and New York-based venture capital firm focused on frontier technologies, including artificial intelligence (AI), augmented reality (AR), virtual reality (VR), and robotics. Founded in 2017 by Andrew Murphy, Doug Clinton, and Gene Munster, the firm invests primarily in early-stage companies that are at the intersection of these emerging technologies. Loup Ventures is research-driven, leveraging in-depth analysis and insights to guide its investment decisions. Notable investments include Neurable, an AI company advancing brain-computer interfaces, and Skupos, a platform providing data solutions for convenience stores. The firm is known for its focus on high-impact sectors like neurotechnology, and the future of transportation, with its portfolio companies aiming to shape the way humans interact with machines and the digital world. Geographically, Loup Ventures focuses on investments across the U.S., with its team frequently engaging in thought leadership through articles and podcasts on technological trends. Their investment strategy emphasizes deep involvement, supporting founders not only financially but also with insights derived from their rigorous market research. The team, led by Gene Munster, a well-known tech analyst, and Andrew Murphy, brings extensive experience in tech and finance. Loup Ventures prefers a hands-on approach, often leading rounds and staying actively involved in guiding startups to scale. Startups looking to attract their attention should highlight disruptive tech in AI or AR, showcasing robust market research and a clear vision for the future.

Lowercarbon Capital, founded in 2018 by Chris and Crystal Sacca, is a venture capital firm dedicated to combating climate change through investments in innovative technologies. Based in Jackson, Wyoming, the firm focuses on backing companies that reduce CO2 emissions, remove existing carbon from the atmosphere, and develop solutions to mitigate the impacts of climate change. Notable investments include Lilac Solutions, which is revolutionizing lithium extraction; Solugen, which produces chemicals using enzymes instead of oil; Commonwealth Fusion Systems, working on fusion energy; and Mosa Meat, creating lab-grown meat to reduce livestock emissions. Lowercarbon Capital has invested in over 160 companies, aiming to combine hard science with ambitious goals to tackle climate challenges. The firm’s strategy emphasizes both financial returns and environmental impact, supporting startups from the R&D stage to seed funding with checks ranging from $50,000 to $1 million. Their comprehensive approach includes not only capital but also strategic guidance and support for founders through a robust ecosystem of industry experts and fellow entrepreneurs​. Led by a team of experienced investors and scientists, including managing partner Chris Sacca, Lowercarbon Capital is positioned at the forefront of climate tech innovation, making significant strides in various sectors such as energy, agriculture, and industrial materials.

Loyal VC is a global venture fund established in 2018 that operates a startup index fund with over 350 investments across more than 60 countries. The firm is known for its unique gate-stage investment process, which reduces systemic bias and aims to unlock greater returns. This process involves multiple rounds of diligence and quarterly redemptions, offering flexibility to high-net-worth individuals and institutions. Loyal VC collaborates closely with INSEAD, Founder Institute, and a network of over 1,000 advisors. This extensive network supports a diverse portfolio of founders, with more than 30% of the portfolio companies led by women CEOs and nearly 30% based in emerging markets. The firm places a strong emphasis on social impact, with 80% of its investments aligned with one or more of the UN Sustainable Development Goals (SDGs). Notable investments by Loyal VC include Sama, a company that brings transparency and verifiability to cross-border blue-collar recruitment, and TechStyle, a digital marketplace for sustainable material sourcing in the fashion industry. The firm also supports companies like CurieMD, a telemedicine platform for menopause care, and Milestone, a financial literacy app aimed at helping parents raise financially responsible children. Loyal VC’s investment focus spans various sectors, including cleantech, fintech, healthcare, and more, reflecting their commitment to backing innovative solutions across the globe. For more information, you can visit their official website.

Ludlow Ventures, founded in 2009 and based in Detroit, Michigan, is a venture capital firm that takes a unique approach to investing by emphasizing strong personal relationships with entrepreneurs. The firm focuses on early-stage investments, particularly in the technology sector. Ludlow Ventures has built a robust portfolio, with notable companies such as Honey, a browser extension for online shopping deals acquired by PayPal; Wag, a dog-walking service; and Product Hunt, a platform for discovering new products. The firm has made over 160 investments and has achieved 24 exits, showcasing their ability to identify and support high-potential startups. Other significant investments include Headout, an on-demand mobile platform for booking tours and activities, and CoverTree, an insurtech company focused on property insurance. Ludlow Ventures operates with a philosophy of "VC without ego," striving to be collaborative and supportive partners to their portfolio companies. The team, led by Managing Partner Jonathon Triest, prides itself on being deeply involved in the success of the startups they back, providing not just capital but also strategic advice and resources.

Lumen Ventures is a Rome-based early-stage venture capital firm that focuses on investing in technology-driven startups, particularly at the seed stage. Established as the first Simple Investment Company (SiS) in Italy, Lumen Ventures manages a €25 million fund aimed at backing high-potential tech startups across sectors like fintech, insurtech, healthtech, and foodtech. Lumen Ventures differentiates itself by being led by a team of former entrepreneurs and operators, which gives them a practical understanding of the challenges faced by startups. This experience enables them to provide not only financial support but also strategic guidance to help founders scale their businesses both in Italy and across Europe. The firm typically invests between €100,000 and €1.5 million per company and is particularly keen on supporting second-time founders. By leveraging their industry expertise and entrepreneurial background, the Lumen Ventures team is committed to helping startups build sustainable growth pathways.

Luminous Ventures is a London-based early-stage deep tech venture capital fund that spun out of White Cloud Capital in December 2018 with a $30 million fund. The firm focuses on the application of innovative technologies to healthcare, life sciences, nutrition, food, and agriculture, investing at seed and Series A stages across Europe and North America. Luminous prefers to be the first venture investor in its portfolio companies, backing visionary founders with scientifically grounded breakthroughs at the earliest stages of company formation. Partner Izzy Fox leads the investment team. The fund is now fully deployed and is no longer making new investments. The portfolio of approximately 27 companies spans healthtech, AI, biotech, and food and agriculture. Named portfolio companies include Astroscreen (disinformation detection), Ellipsis Health (mental health voice AI), Hadean (high-performance cloud operating systems), Optellum (AI-based lung cancer diagnostics), Synthace (lab operating systems), Universal Quantum (quantum computing), OVR Health (VR health applications), Vital Bio (point-of-care diagnostics), and Facesoft (sustainable textile face coverings). BioBeats, an earlier portfolio company, was acquired by Huma in April 2020. The fund's most recent investment was Treos Bio in April 2024. Luminous Ventures' thesis was built on the convergence of computational power, biological understanding, and materials science — investing ahead of when these disciplines became mainstream VC themes. The firm prioritized backing founders with credible scientific backgrounds working on problems where technology could fundamentally change outcomes in health and food systems, rather than incremental software applications at the margins of these sectors.

Lumira Ventures is a prominent venture capital firm specializing in life sciences and healthcare investments. Established in 1989 and headquartered in Toronto, Canada, Lumira Ventures has a robust presence across North America, with offices in Toronto, Montreal, Vancouver, and Boston. The firm focuses on backing innovative biotechnology and medical technology companies that have the potential to address significant unmet medical needs and improve healthcare quality globally. The firm's investment portfolio includes a wide range of companies such as Depomed, Guava Technologies, Think Research, and U-Systems, showcasing their diverse interest in biopharmaceuticals and medical devices. Notable recent investments include Antiva Biosciences, developing topical therapies for HPV-related pre-cancerous lesions, and Arclight Therapeutics, focusing on neurodegenerative diseases. Lumira Ventures' investment strategy involves providing substantial support to their portfolio companies, from early-stage funding to strategic guidance. They recently closed their Lumira Ventures IV fund at $220 million, the largest life sciences venture fund ever raised in Canada, highlighting their significant role in the sector. Overall, Lumira Ventures is dedicated to advancing healthcare innovation through strategic investments and active support of pioneering companies in the life sciences domain.

Lunar Ventures is a Berlin-based venture capital firm focused on investing in deep-tech startups across Europe. The firm specializes in early-stage companies, often leading seed rounds with investments ranging from €300K to €1M. Lunar Ventures primarily targets highly technical founders working on breakthrough innovations in fields like artificial intelligence, cryptography, cloud infrastructure, and advanced computing. Their mission is to support visionary entrepreneurs building cutting-edge technologies that address complex, global challenges. What sets Lunar Ventures apart is their deep technical expertise. The team comprises engineers, computer scientists, and tech-bio specialists who provide hands-on support to portfolio companies. This background enables them to understand and back startups tackling the most complex technical problems, often before they generate revenue. The firm is committed to helping these companies scale, offering both financial capital and strategic guidance throughout their development journey. Lunar’s portfolio reflects its commitment to innovation, featuring companies such as Zama, which focuses on privacy-preserving AI, and Bedrock, which is revolutionizing ocean floor mapping with autonomous underwater vehicles. Lunar’s approach to investing emphasizes a long-term vision, partnering with startups from seed to Series A and beyond, helping them navigate the challenges of growth in the deep-tech ecosystem. Based in Berlin, Lunar Ventures operates across Europe, working with companies that are redefining industries through science and engineering, and making an impact in sectors ranging from AI to biotech and beyond.

Lux Capital is a leading venture capital firm renowned for its investments in groundbreaking science and technology ventures. With a portfolio boasting companies like Recursion Pharmaceuticals, Desktop Metal, and Matterport, Lux Capital focuses on industries such as biotechnology, material science, and artificial intelligence. The firm invests primarily in early-stage startups but is versatile enough to support companies through later stages as well. Lux Capital is geographically centered in the United States, with a strong presence in New York and Silicon Valley. Their investment strategy is defined by backing counter-conventional ideas that push the boundaries of current technology and science. They are known for making substantial investments, often leading funding rounds, and providing robust support to their portfolio companies to ensure their long-term success. The firm is managed by an experienced team including co-founders Peter Hébert, Robert Paull, and Joshua Wolfe. Their approach is hands-on, offering not just capital but also strategic guidance, networking opportunities, and operational support. Lux Capital values innovative pitches and prefers to be approached with well-researched and transformative ideas. In recent years, Lux Capital has been highly active, raising significant funds like the $1.15 billion for its eighth fund. The firm’s commitment to pioneering technologies is evident in their diverse investments, from AI-driven biotech firms like Evolutionary Scale to innovative aerospace companies like Planet.

M Ventures is the strategic corporate venture capital fund of Merck KGaA (Darmstadt, Germany), created in 2009 and headquartered in Amsterdam, Netherlands, with additional offices in Germany, Israel, and the United States. The fund invests with dual strategic and financial objectives across biotechnology and technology, covering four areas: healthcare drug development, life science tools, electronics, and frontier technology and sustainability. In 2021, Merck expanded M Ventures with an additional €600 million commitment — the third increase since the fund's creation — enabling larger and more frequent investments. The team of seven is led by CEO Howard H. Thaw. M Ventures leads rounds and has made 133 investments with 20 portfolio exits, the most recent being Calypso Biotech in January 2024. A recent landmark deal was the co-led $75.5 million oversubscribed Series A for Actithera in July 2025, a radiopharmaceutical biotech developing next-generation radioligand therapies. The biotech portfolio focuses on emerging biotechnologies leading to differentiated drugs, R&D tools, and platforms with significant potential to improve patient outcomes. The technology portfolio invests in companies developing new solutions for information access, storage, processing, and display, as well as sustainability challenges. Geographic scope is global, with concentrations in Europe, Israel, and the United States. M Ventures takes an active role in portfolio companies and facilitates seed-stage company creation, early-stage syndicated investments, and the creation and funding of Merck spin-offs. Portfolio companies benefit from Merck's deep scientific networks, laboratory infrastructure, and relationships with global pharmaceutical and specialty chemical companies across Merck's three business sectors: life science, healthcare, and electronics.

M12, Microsoft's venture fund, focuses on early-stage investments, primarily in Series A and B rounds. Established in 2016, M12 has quickly become a significant player in the venture capital landscape, leveraging Microsoft's extensive network and resources to support its portfolio companies. M12's investment areas include AI, cloud infrastructure, cybersecurity, developer tools, vertical SaaS, and emerging technologies like Web3 and gaming. Notable investments by M12 include companies such as SpaceX, Addepar, GoPuff, BitGo, and Dataminr. Additionally, M12 has backed promising startups like BlueVine in vertical SaaS, Bolster in cybersecurity, and Bonsai in AI. M12 also focuses on fostering innovative solutions in autonomous systems and frontier technologies​. The fund operates with a close alignment to Microsoft, which allows it to provide unique benefits and opportunities for its portfolio companies, such as integrations with Microsoft Azure and other enterprise solutions. This strategic alignment helps startups accelerate their growth and expand their market reach by leveraging Microsoft's extensive ecosystem.

M13 is a venture capital firm based in Santa Monica, California, known for its early-stage investments in disruptive technology and consumer-focused companies. Founded in 2016 by brothers Carter and Courtney Reum, M13 has established a robust portfolio that includes notable companies such as Ring, Cue, Daily Harvest, FabFitFun, ClassPass, Matterport, and Capsule. M13's investment strategy spans several sectors including health, commerce, work, and money, with a strong focus on infrastructure technologies such as AI and web3. The firm leverages its Propulsion Platform, which combines operational expertise and strategic guidance to help startups scale efficiently. This platform ensures that each founder receives tailored support, significantly enhancing their chances of success. M13 has recently launched its third fund, raising $400 million to continue backing early-stage teams. Their approach involves writing checks of up to $15 million from Seed to Series B stages, often leading the investment rounds. This fund aims to capitalize on the evolving consumer behavior and the growing importance of horizontal technology layers, including blockchain-based applications governed through tokens.

M25 is an early-stage venture capital firm based in Chicago, focusing on investments in startups headquartered in the Midwest. Founded in 2015, M25 has quickly become one of the most active seed investors in the region, with over 90 investments across a variety of industries, including AI, fintech, e-commerce, healthcare, and software. Notable investments from M25 include companies like Upsie, a warranty services provider; Avail, a platform for landlords and tenants; and PactSafe, a contract acceptance platform. The firm has a strong focus on supporting innovative and high-growth potential startups, leveraging their extensive network and resources to help these companies scale effectively. M25’s investment strategy involves making initial investments ranging from $500,000 to $1.5 million and often taking board seats to provide strategic guidance. The firm emphasizes a data-driven approach to investment decisions and maintains a hands-on relationship with its portfolio companies to support their growth and success.

Magnet Ventures is a San Francisco-based venture capital firm founded in 2016 by Georgia Lu. The firm primarily focuses on early-stage investments across biotechnology, healthcare, artificial intelligence, and other innovative technology sectors. Magnet Ventures has gained recognition for its strategic investments in companies leveraging advanced technology to transform fields such as drug discovery, diagnostics, and robotics. The firm's investment strategy is characterized by close collaboration with founders, offering not just capital but also strategic guidance and operational support. Magnet Ventures has invested in companies like Flux Biosciences, Atom Bioworks, and CloudMinds Robotics, showcasing its interest in high-potential sectors where AI intersects with biotech. The firm has achieved notable exits, including the sale of CloudMinds Robotics, further solidifying its reputation as a valuable partner for tech-driven startups. Magnet Ventures is led by a small but experienced team, including partners based in the U.S. with deep backgrounds in science, technology, and business. The firm continues to expand its portfolio by focusing on companies that are poised to drive future innovations across a range of critical industries, making it a key player in the global tech investment space.

Magnetic Ventures is a Miami Beach-based venture capital firm founded in 2018 by Christine Aylward. The firm specializes in early-stage investments, primarily focusing on companies at the intersection of technology and life sciences. With a strong emphasis on AI, machine learning, and biotech, Magnetic Ventures backs founders who are developing transformative solutions in healthcare. Their investment portfolio includes cutting-edge companies like Deep Genomics, Spotlight Therapeutics, and Paradigm, which are revolutionizing areas like drug discovery, gene editing, and clinical research. Magnetic Ventures typically makes initial investments ranging from $1 million to $6 million, entering at seed or Series A stages. The firm is deeply involved in supporting its portfolio companies throughout their growth, leveraging its extensive experience in healthcare regulation and commercialization. Their geographical focus is North America and Europe, with offices in Miami, Boston, and Research Triangle Park​. This hands-on approach and a mission to advance patient care through technology have made Magnetic Ventures a key player in driving innovation across the healthcare landscape.

Main Sequence Ventures, founded in 2017 and backed by Australia's national science agency CSIRO, is a venture capital firm that focuses on deep tech and frontier technologies. The firm is headquartered in Australia and aims to solve significant global challenges through its investments. Main Sequence has a unique "venture science" model, which starts by identifying big challenges and bringing together science, people, and investment to create and fund companies that can address these issues. Main Sequence Ventures has built a strong portfolio with notable companies such as Q-CTRL, which makes quantum technology useful; Gilmour Space, which focuses on efficient satellite launches; and Emesent, a leader in robotics and autonomy technology. Other significant investments include Myriota, which provides low-cost satellite connectivity, and V2food, which develops sustainable meat alternatives. The firm's second fund, which raised $250 million, focuses on areas such as decarbonization, healthcare, and space technology. This fund supports companies like Kasada, a cybersecurity firm stopping bot attacks, and RapidAIM, which offers biosecurity solutions for pest management. Main Sequence Ventures is dedicated to leveraging scientific discoveries to create impactful, high-growth companies that can address some of the world's most pressing challenges. Their strategic investment approach and strong support for portfolio companies highlight their commitment to driving innovation and technological advancement globally.

Maine Venture Fund (MVF) is a professionally managed venture capital fund created by an act of the Maine Legislature in 1995 and actively investing in Maine companies since 1997. Based in Newport, Maine, MVF invests exclusively in Maine-based businesses with high growth potential and public benefit. The fund operates as an evergreen revolving structure capitalized at $19.5 million, recycling all income and investment returns for deployment into additional Maine companies. Managing Director Joe Powers and Principal Nina Scheepers lead investment activities alongside running the Maine Startup Challenge, an initiative designed to identify and support early-stage entrepreneurs across the state. MVF's initial check size is typically $100,000 in convertible preferred stock, investing across nearly any industry. The fund has made 46 investments alongside over 400 co-investors including angel investors, venture funds, and institutional partners. In 2025, the fund deployed $3.3 million into Maine companies — above typical volume — driven by a growing pipeline and access to the FAME Grow Maine federal program. In 2024, only $1.2 million was deployed due to market slowdown. Recent investments include VETRO (Series C, May 2025), with earlier portfolio companies including Kinotek, Hoopsy, and Metis Health Technologies. The most recent exit was Circa in June 2024. MVF's legislative mandate distinguishes it from commercial venture funds: returns must be recycled into additional Maine investments rather than distributed to outside LPs, creating an alignment with long-term state economic development. This structure has allowed the fund to remain active for nearly three decades as a consistent early-stage capital source for Maine entrepreneurs who may not fit the geographic preferences of coastal VC firms.

Majycc Capital is a prominent French venture capital firm that focuses on revolutionizing the healthcare sector through strategic investments in innovative startups. Established in 2022 through the merger of Majycc eSanté Invest and UI Investissement, the firm now manages over €700 million, primarily dedicated to eHealth, MedTech, and BioTech ventures. Majycc Capital is particularly active in the Series A and B funding stages, where it seeks out high-potential startups across France and Europe that are positioned to deliver transformative advancements in healthcare. The firm's investment strategy goes beyond financial support. Leveraging its deep connections within the healthcare ecosystem, Majycc Capital provides comprehensive strategic assistance to its portfolio companies. This includes guidance on navigating complex regulatory pathways, insights into market dynamics, and support in business development—key elements that are crucial for scaling healthcare innovations. Majycc’s extensive network within the healthcare industry, including partnerships with healthcare manufacturers and private clinic groups, further amplifies the growth potential of the startups it backs. Majycc Capital’s commitment to innovation is underscored by its regional presence, with 13 offices throughout France, ensuring that it remains closely involved with local economies and emerging companies. The firm’s dedicated team, led by experienced professionals, is deeply invested in the success of its portfolio companies, working tirelessly to ensure they achieve their full potential in the competitive healthcare market​.

Maki.vc is a seed-stage venture capital firm that partners with deep tech and brand-driven startups focused on challenging category norms. Founded in 2018, Maki.vc invests in early-stage companies from their inception to Series A, emphasizing scientific advancements and unique customer understanding. Maki.vc has a global mandate, with a strong presence in the Nordics. The firm’s portfolio includes companies across various sectors such as AI, quantum computing, and sustainability. Notable investments include IQM, a leader in quantum computing; Spinnova, which develops sustainable textiles; and Onego Bio, which creates animal-free egg protein using novel technology. The firm’s approach goes beyond providing capital. Maki.vc supports its portfolio companies through Maki House, a platform that offers strategic guidance and a network of experts to help startups scale and achieve long-term success. Their investment philosophy centers on future-proofing companies by integrating ESG principles into their operations from the start, ensuring sustainability and long-term profitability.

Mana Ventures is a San Francisco-based venture capital firm that focuses on early to growth-stage investments, primarily in technology-driven sectors. Founded in 2016, the firm has built a diverse portfolio that includes companies across AI, software, consumer tech, healthtech, and more. Mana Ventures aims to back startups that are redefining industries through innovation, providing not only capital but also strategic support to help them scale. The firm’s portfolio features high-profile companies like Unity Technologies, a leading platform for game development, and Monarch, which focuses on AI-powered autonomous tractors. Mana Ventures is also known for its investments in companies like Synctera, a fintech software suite, and Odeko, which offers solutions for coffee businesses. Their strategic approach involves partnering with entrepreneurs from early stages and guiding them through product development, market expansion, and subsequent funding rounds. Mana Ventures emphasizes a hands-on approach, often leveraging its extensive network of LPs, founders, and industry specialists to support its portfolio companies. This network is designed to provide value beyond funding, including access to strategic partnerships, recruitment, and revenue-driving opportunities. With a keen focus on innovation and scalable tech solutions, Mana Ventures continues to shape and support startups that have the potential to lead their industries.

Mandashi is a Sheffield-based family office investment firm focused on supporting early-stage startups with innovative and impactful solutions. Founded by Dr. Andy Evans and Sheila Gupta, Mandashi aims to invest in sectors that address real-world challenges, emphasizing sustainability, healthcare, and technological advancements. The firm operates with a mission to mentor and inspire entrepreneurs, guiding them to build successful businesses that contribute positively to the community. Mandashi's portfolio reflects its commitment to diverse industries, with investments in companies like FourJaw, which enhances manufacturing productivity through data analytics, and Rarecan, a platform improving research for rare cancers. The firm also backs ventures such as Atelerix, which develops innovative methods for preserving biological materials, and GitLife Biotech, focusing on bio-asset intellectual property. The investment approach at Mandashi extends beyond capital; they provide strategic support and networking opportunities, helping startups transform their vision into scalable solutions. The firm actively promotes ethical business practices, long-term growth, and community engagement, highlighting their belief in responsible and sustainable entrepreneurship. Mandashi’s team, led by founders with a track record of successful ventures, brings deep expertise and a hands-on approach to every partnership.

Mandi Ventures is an early-stage venture capital fund based in São Paulo, Brazil, with additional offices in Brussels. The fund focuses on investing in disruptive technologies within the food, agriculture, and climate tech sectors. Mandi Ventures primarily targets startups involved in novel foods, biotech, life sciences, robotics, and precision farming, aiming to reshape how we produce and consume food. Their global investment reach includes startups across the Americas, Europe, and Israel. Mandi Ventures supports seed-stage companies, offering not just capital but also strategic business expertise to help startups commercialize their innovations. They focus on areas like supply chain logistics, wellness, sustainability, and SaaS platforms within the food and agriculture ecosystem. Notable investments include companies driving innovation in biotech and precision farming, ensuring that the fund stays at the forefront of transformative food technologies. With a strong network and industry connections, Mandi Ventures plays an active role in guiding its portfolio companies through their growth stages, from scaling operations to market expansion.

Manta Ray Ventures is an early-stage venture capital firm based in London, founded by Sebastian Kulczyk. The firm focuses on backing mission-driven founders who aim to address significant global challenges using advanced technologies. Manta Ray Ventures provides flexible and patient capital, leveraging their resources and networks to support their portfolio companies. Their diverse portfolio includes notable investments such as Volocopter, a manufacturer of electric copters for urban mobility; Astranis, a developer of satellite-based communication services; and Bluu Biosciences, focused on food and agriculture technology. They also have investments in companies like Epic Games, the creator of the popular game Fortnite, and Juvena Therapeutics, which is involved in drug discovery and clinical trials. Manta Ray Ventures has achieved significant exits, including the acquisition of Frontier Car Group by OLX Group and the merger of Forge Platform. The firm has also seen one of its portfolio companies, Bridge, go public on the Tokyo Stock Exchange. Led by a team of experienced professionals, including Managing Partner Lawrence Barclay and Partner Leah von Siemens, Manta Ray Ventures is dedicated to fostering innovation and supporting the growth of transformative technologies across various industries.

March Capital, established in 2014 and based in Santa Monica, California, is a venture growth firm focused on next-generation technology companies. The firm emphasizes sectors such as enterprise AI, fintech, and commerce enablement, aiming to partner with visionary entrepreneurs and support their growth to market leadership. Notable investments in March Capital's portfolio include CrowdStrike, a leader in cybersecurity; BillDesk, India's premier payments network; and Canva, an online design platform. They have also invested in companies like ActionIQ, a customer data platform, and ASAPP, an AI software company automating customer service. March Capital has seen successful exits from companies such as CarTrade, an online automotive marketplace, and Forescout, a cybersecurity firm. The firm is known for its collaborative approach, working closely with portfolio companies to provide strategic guidance and leveraging their extensive network to drive growth and success. They focus on building concentrated portfolios and doubling down on high-potential investments, ensuring significant impact and returns. March Capital also hosts The Montgomery Summit, a premier technology conference that gathers leading entrepreneurs, investors, and corporate executives to foster relationships and catalyze growth for portfolio companies.

Marcy Venture Partners (MVP), co-founded in 2018 by Shawn "JAY-Z" Carter, Jay Brown, and Larry Marcus, is a venture capital firm based in San Francisco. The firm focuses on investing in consumer and culture-driven companies that emphasize sustainability, inclusivity, accessibility, empowerment, and health & wellness. MVP's approach involves partnering with innovative businesses that are led by exceptional management teams and have strong brand values, outstanding products, and clear growth trajectories​. The firm has raised significant capital, closing its second fund with $325 million, bringing total assets under management to around $600 million. MVP has made investments in companies such as Therabody, Savage X Fenty, and Wheels, demonstrating a keen interest in diverse and impactful sectors. MVP is renowned for its robust support network and hands-on involvement, providing not just capital but also strategic guidance and industry connections to help its portfolio companies scale effectively​.

Maroon Venture Partners Fund is a university-linked venture capital fund based in Amherst, Massachusetts, investing exclusively in early-stage companies connected to the University of Massachusetts Amherst. Founded in January 2017 as the first venture capital fund at UMass Amherst, it was anchored by alumnus Paul Manning (UMass class of 1977, founder of PBM Capital Group, a healthcare-focused private equity firm) alongside UMass Amherst as institutional co-investor. Fund Manager Charlie Johnson, a faculty member at the Isenberg School of Management, oversees day-to-day operations, supported by an investment committee including John Brooks, Nancy Confrey, Mike Masterson, Ameeta Soni, and Steve Willis. Fund I was a $6 million vehicle that deployed approximately $5 million across 13 companies led by UMass faculty, students, and alumni, completing its investment period in 2023. Typical check sizes are $100,000 to $300,000, often representing a company's first outside equity capital. Fund II launched in January 2024 with $3.2 million in commitments against a $5 million target, backed by Manning, UMass Amherst, and additional alumni LPs. The fund operates on a ten-year harvest horizon. Sectors served include biotech, diagnostics, advanced materials, and food and beverage. Portfolio companies include Myrias Optics (wafer-level metaoptics, which raised a $2.1 million Seed 1 round in January 2026), 88 Acres (allergen-friendly foods, founded by Nicole Ledoux, UMass class of 2001), florrent, Latde Diagnostics, and HasenTech. The fund's narrow mandate — backing only ventures with genuine UMass Amherst roots — gives it privileged early access to the university's research pipeline and entrepreneurial ecosystem. Portfolio companies benefit from faculty expertise, the university's laboratory infrastructure, and a growing alumni investor network that has grown with each successive fund.

MarsBio is a Los Angeles-based venture capital fund that focuses on investing in pre-seed and seed-stage biotech startups. The firm specializes in biosciences and frontier technologies, targeting innovations in healthcare, therapeutics, synthetic biology, and the future of food. With check sizes ranging from $250K to $500K, MarsBio supports startups that push the boundaries of biology, using it as a tool for manufacturing and sustainable solutions. Their portfolio reflects an interest in companies working on immunology, oncology, neuroscience, and bio-enabling technologies, such as research tools and bioelectronics. Co-founded by Rob Rhinehart, best known for creating Soylent, MarsBio aims to back visionary founders with disruptive ideas. The firm emphasizes its support for entrepreneurs tackling complex problems, particularly those related to sustainable food supply chains and novel healthcare solutions. MarsBio’s strategy is to engage deeply with founders at the earliest stages, helping them scale innovative solutions that have the potential to redefine industries. MarsBio primarily invests in U.S.-based companies and leverages its expertise and network to drive transformational progress in biosciences. They’re especially drawn to startups that are pioneering new technologies that could shape the next era of healthcare and sustainable living.

Martlet Capital is an early-stage venture capital firm based in Cambridge, UK, focused on deep technology and life sciences B2B startups. Since its inception in 2011, Martlet Capital has invested in over 70 companies, providing patient capital to high-growth potential ventures. Their portfolio spans sectors like artificial intelligence, digital health, personalized medicine, engineering, IoT, new materials, and quantum technologies. Notable investments include Echion Technologies, known for their superfast-charging lithium-ion batteries, and IESO Digital Health, which provides real-time cognitive behavioral therapy online. They have also invested in companies like Converge, developing wireless sensor networks for real-time construction monitoring, and Dogtooth Technologies, which creates autonomous robots for productivity enhancement. Martlet Capital typically leads funding rounds and supports its portfolio companies beyond capital with strategic guidance, network access, and operational expertise. Their successful exits include Arachnys, Audio Analytic, and Cambridge CMOS Sensors. Martlet Capital's team comprises experienced investors and entrepreneurs, who actively engage in nurturing startups from early commercialization stages to scaling. Their investment strategy focuses on fostering innovation and driving growth in the UK, particularly within the Cambridge tech ecosystem. For startups seeking investment, Martlet Capital looks for innovative solutions with scalable business models in deep tech and life sciences. They prioritize strong leadership teams and groundbreaking technologies that can make a significant impact on their respective industries.

Marubeni Corporation, founded in 1858 and incorporated in 1949, is a prominent Japanese general trading company headquartered in Tokyo. The company operates across numerous sectors including lifestyle, IT solutions, food, agriculture, chemicals, metals and mineral resources, energy, power, infrastructure projects, aerospace, shipping, finance, leasing, real estate, and industrial machinery. Marubeni is committed to sustainability and innovation, aiming to create solutions that foster positive societal impact while maintaining financial performance. This commitment is reflected in their investments and operations across diverse industries worldwide. The company's philosophy of "Fairness, Innovation, and Harmony" drives its vision for a sustainable and prosperous future. The company has a robust global network with over 4,300 employees and numerous subsidiaries and affiliates, highlighting its significant presence and influence in the international market. Marubeni's extensive operations and strategic investments underscore its role as a key player in global trading and investment.

MassMutual Ventures (MMV) is a global venture capital firm that invests in a range of sectors, including enterprise software, cybersecurity, financial technology, digital health, and climate technology. Founded in 2014 and based in Boston, MMV also has offices in London and Singapore. The firm manages over $1 billion in investment capital and focuses on accelerating the growth of its portfolio companies by providing capital, connections, and strategic advice. Notable investments by MMV include Prove, a leader in digital identity solutions; Daye, a gynecological health startup; and Griffin, a developer-friendly Banking as a Service platform. The firm's portfolio spans across various stages of investment, from seed to growth stage, with typical check sizes ranging from $100,000 to $5 million. In 2022, MMV launched a $100 million Climate Technology Fund to invest in early and growth-stage companies addressing climate change. This fund aims to support 15 to 20 companies developing solutions to mitigate, measure, and manage climate change impacts, further expanding MMV's commitment to sustainable innovation​. The team at MMV includes experienced investors, former entrepreneurs, and operators, such as Doug Russell, the Managing Partner and Head of MMV, and Ryan Collins, the Managing Partner for Europe and APAC. Their deep industry expertise and extensive network help portfolio companies scale and succeed in competitive markets.

MassVentures, established in 1978 as the Massachusetts Technology Development Corporation, is a venture capital firm dedicated to supporting early-stage technology startups in Massachusetts. With a mission to bridge the capital gap for startups, MassVentures has invested $91.9 million in 152 companies from its inception through June 2019. The firm focuses on diverse sectors including life sciences, robotics, and advanced manufacturing, and typically makes initial investments of $250,000 to $500,000. Notable investments include Battery Resourcers, Inkbit, and Pison. Additionally, MassVentures administers the Small Business Innovation Research Targeted Technologies (SBIR-TT) grant program, which has awarded $22.1 million to 79 companies since 2012. This program supports the commercialization of innovations emerging from academic research and small businesses, fostering technological advancement and job creation in the state. MassVentures is led by an 11-member board of directors, predominantly from the private sector, and operates with a small team based in Boston. The firm not only provides financial support but also strategic guidance and operational expertise to help startups scale successfully. Through its investments and grant programs, MassVentures plays a crucial role in the growth of Massachusetts' innovation ecosystem, aiming to enhance the state's economic development by nurturing high-potential startups.

Material Impact, founded in 2015 by Adam Sharkawy and Carmichael Roberts, is a venture capital firm based in Boston, Massachusetts, that focuses on transforming material science innovations into impactful real-world applications. The firm is dedicated to addressing large-scale problems related to food, water, sustainable manufacturing, transportation, mobility, and healthcare through its investments in deep tech companies. Material Impact's portfolio includes notable companies such as DetraPel, Bloomer Tech, Folio Photonics, and Nohbo. These investments span a range of industries, including specialty chemicals, healthcare monitoring equipment, IT storage, and personal products. The firm’s hands-on approach to building companies involves working closely with founders to guide them through critical growth stages​. In 2023, Material Impact announced its $352 million Fund III, aimed at continuing its mission to support early-stage startups that leverage material science to solve pressing global challenges. This new fund allows Material Impact to take larger ownership stakes while maintaining its active role in company development. The firm's commitment to diversity and impact is reflected in its alignment with the United Nations Sustainable Development Goals and its diverse leadership team​. For entrepreneurs interested in partnering with Material Impact, the firm values innovations that have strong scientific foundations and the potential to address significant human needs. Material Impact provides not only capital but also strategic and operational support, often embedding its team members within portfolio companies to ensure their success.

Matrix Partners is a powerhouse in early-stage venture capital, boasting over four decades of experience and $4 billion in assets under management. Their portfolio spans transformative startups like Canva, Afterpay, Oculus, and Hubspot, among 65+ IPOs and 110+ acquisitions. With offices in San Francisco and Boston, Matrix invests globally, focusing on the U.S., India, and China. Their sweet spot is in sectors like AI, fintech, digital health, and B2B SaaS. Matrix is known for its commitment to backing founders from seed through Series A, providing checks ranging from $100K to $1M. They emphasize patience, nurturing relationships with company builders and former founders, helping them scale effectively. While they often lead rounds, Matrix also co-invests, partnering with top VCs like Y Combinator and Andreessen Horowitz. Key team members include Pranay Desai and Paul Sherer in San Francisco, and they maintain a reputation for being hands-on, leveraging deep expertise across diverse tech-driven industries. Entrepreneurs seeking funding should approach Matrix with a clear vision for scalable innovation, as the firm is laser-focused on high-impact, technology-driven ventures.

Maven Ventures is a seed-stage venture capital firm specializing in consumer software startups. With a notable track record, Maven has backed major successes like Zoom, Cruise, and Epic!, achieving significant exits and IPOs. Founded in 2013, the firm has maintained a focused strategy, supporting around 50 high-potential startups with investments typically ranging from $750K to $1M. The firm is keenly interested in emerging consumer trends and technologies, investing in sectors like digital health, autonomous vehicles, fintech, and AI-driven solutions. Geographic focus primarily includes the United States, particularly Silicon Valley, but Maven also invests in global opportunities. Maven Ventures' strategy is highly selective, with a small team providing hands-on support to a concentrated portfolio. The team, led by seasoned investors like Jim Scheinman, focuses on building deep relationships with founders, offering critical guidance on marketing, product development, and go-to-market strategies. Recent investments include startups like Hello Heart, which provides mobile solutions for heart health, and Wildtype, a company pioneering lab-grown seafood. The firm has a proactive approach to diversity, supporting a range of women-led and minority-led startups. Maven Ventures prefers to be approached through a well-articulated pitch that demonstrates a strong market need and scalable solution. With a reputation for nurturing bold founders and transformative ideas, Maven Ventures remains a prominent player in the VC landscape, consistently driving innovation and impactful growth in the consumer tech sector​.

Maverick Ventures is the venture capital arm of Maverick Capital, a multi-billion dollar hedge fund platform managing approximately $12.5 billion in AUM. Founded in 2015 in San Francisco, Maverick Ventures operates as an evergreen fund structurally integrated with the hedge fund platform, giving portfolio companies access to hedge-fund-grade analysts and public company networks that conventional VC firms cannot match. By March 2025, the firm had raised over $240 million for its fourth vintage — led by Kindred Capital with Y Combinator, Rebel Fund, and Concept Ventures joining — bringing total capital raised to $855 million and AUM to $1.4 billion. Managing Partner David Singer, a repeat founding CEO of three public companies, leads a deliberate five-person investing team that backs only a select number of companies per year to enable deep engagement with each founder. The firm focuses on healthcare innovation and enterprise AI, investing from Seed through Series C and beyond with check sizes typically between $3 million and $50 million. Maverick leads rounds. Across 83 total investments, the portfolio has produced 10 unicorns, 12 IPOs, and 37 acquisitions. Notable exits include Hims and Hers (seed investor through its 2021 IPO), BioCatch (sold to Permira for $1.3 billion in 2024), Coupang, One Medical, and Tata 1mg. Recent investments include Oula Health ($28 million Series B co-led, December 2024) and Garner (healthcare technology, February 2026). Approximately 30 percent of fund capital comes from Maverick partners and employees — the largest single LP — a structural feature that aligns the partnership's own capital with founder outcomes. Maverick's integration with a mature public markets platform allows it to support companies from first institutional check through post-IPO holding, providing continuity of partnership that few venture platforms can offer.

Maveron, a consumer-only venture capital firm, was founded in 1998 by Dan Levitan and Howard Schultz, the visionary behind Starbucks. The firm focuses on early-stage investments in transformative consumer brands. With a keen understanding of consumer behavior and market trends, Maveron has built a diverse portfolio that includes notable companies like Allbirds, Everlane, and Zulily. Maveron operates with a mission to back entrepreneurs who aim to change how people live, work, learn, play, eat, and stay well. Their investments span various consumer sectors such as health and wellness, e-commerce, and food innovation. Some of their prominent exits include eBay, Trupanion, and Potbelly Sandwich Works. The firm recently raised $225 million for its eighth fund, continuing its legacy of identifying and supporting early-stage consumer startups. Maveron's team, led by experienced partners like Dan Levitan and Jason Stoffer, brings deep industry knowledge and a commitment to fostering long-term partnerships with entrepreneurs.

Max Ventures, founded in 2013 by Ryan Darnell and Sophie Stenbeck, is a dynamic seed-stage venture capital firm based in New York. Notable for its early investments in companies like Boxed, ZoomCar, Button, and Drone Racing League, Max Ventures focuses on consumer tech and health-tech startups. The fund targets North American markets and emphasizes investing in founders with unique consumer insights and relentless drive. Max Ventures typically makes initial investments ranging from $750K to $1M, often leading the rounds. Their strategy involves a hands-on approach, leveraging their extensive network to support portfolio companies in achieving significant growth. The fund is particularly interested in startups within the fashion/beauty, food and beverage, internet and web services, real estate, and software industries. The team, including key figures like Managing Partner Matthew Weinberg, prides itself on its ability to identify and nurture innovative talent. Startups looking to approach Max Ventures should focus on demonstrating strong consumer insight and a clear execution plan. Recently, the firm has been active with investments like UnityAI in healthcare technology, showcasing their ongoing commitment to pioneering advancements in tech.

Mayfield is a renowned venture capital firm founded in 1969, with a focus on early-stage investments. The firm is based in Menlo Park, California, and has a strong presence in the U.S. and India. Mayfield has made significant contributions to the tech industry, backing over 852 companies, including notable names like Lyft, Couchbase, and Poshmark. Mayfield’s portfolio showcases a diverse range of sectors, emphasizing artificial intelligence, enterprise software, consumer tech, semiconductors, and human and planetary health. Some of their standout investments include Unstoppable Domains, Amagi, and BigPanda, which have grown into unicorns under their guidance. The firm has also successfully shepherded companies to IPO, such as Lyft and Couchbase, and facilitated numerous high-profile acquisitions. The firm operates with a "people-first" investment philosophy, aiming to partner with visionary entrepreneurs from inception through growth stages. They typically invest in Seed, Series A, and Series B rounds, providing not only capital but also strategic support and mentorship. Mayfield's investment team includes seasoned partners like Navin Chaddha and Ursheet Parikh, who bring extensive industry experience and a track record of successful exits. Mayfield's investment strategy involves close collaboration with founders, focusing on building enduring companies that can achieve market leadership. Founders looking to connect with Mayfield should highlight their innovative solutions and potential for significant impact, aligning with the firm’s mission to back transformative technologies.

MariaMazarine Ventures is a Chicago-based venture capital firm dedicated to addressing the global water crisis through technology. Founded in 2018, Mazarine exclusively invests in early-stage startups that are developing innovative solutions for managing water and wastewater-related risks across various industries. These sectors include agriculture, aquaculture, climate tech, and industrial applications, among others. The firm operates multiple funds, each with a unique focus. Fund II, for instance, targets companies with proven commercial traction—often nearing $1 million in annual sales—and intellectual property rooted in fields like chemistry, data science, and materials science. Mazarine typically leads seed and early Series A rounds, cutting checks between $25,000 and $500,000, and often continues to support its portfolio companies through follow-on investments. Mazarine’s investment strategy is centered on mitigating critical risks—such as public health, environmental protection, and business continuity—posed by water scarcity and quality issues. The firm’s approach extends beyond financial backing; it leverages a network of experienced operators and co-investors to provide strategic support, helping startups scale and achieve meaningful impact. The leadership team, including co-founders John Robinson, Pete Nassos, and Anders Hallsby, brings decades of experience in commercializing water and wastewater technologies. Mazarine’s rigorous focus on ESG (Environmental, Social, and Governance) metrics underscores its commitment to not only financial returns but also substantial environmental and social impact​. wll do on Thu

in 2001, MBVP primarily focuses on medical device startups, particularly those addressing musculoskeletal diseases. Notable investments include startups acquired by industry giants like Johnson & Johnson, Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical (now part of Stryker). MBVP's strategy emphasizes providing not just capital but also strategic direction, leveraging their deep industry connections and expertise. They typically invest at all stages of development, ensuring that startups have the support they need from inception through to exit. The firm is known for its active role in the Musculoskeletal New Ventures Conference, a testament to its leadership in the sector. The team is led by co-founder Gary Stevenson, whose background includes significant roles in healthcare investment banking, equity research, and general management at Abbott Laboratories. Gary's comprehensive experience and his educational background, including an MBA from Northwestern University's Kellogg School of Management, underscore the firm's robust leadership. MBVP prefers to be approached by startups with a clear, compelling value proposition in the life sciences sector. They are known for writing substantial checks and often lead investment rounds. Their involvement in over 50 startups highlights their active investment approach and commitment to advancing medical innovations​.

MBX Capital, established in 2015, is a venture capital firm headquartered in Claymont, Delaware. The firm specializes in early-stage investments within the healthcare and life sciences sectors, focusing on pre-seed, seed, and Series A rounds. MBX Capital has a robust portfolio that includes companies like Luna, Concert Health, Koneksa Health, Atlas Labs, and Buoy Health​. Notable recent investments by MBX Capital include Vivodyne, which raised $38 million in November 2023, and Macro Trials, which secured $6 million in June 2023. These investments underline the firm's commitment to advancing biotechnology and clinical trials​ (PitchBook)​. Additionally, MBX Capital led a $10.7 million Series A financing for Contraline, supporting the development of innovative medical technologies​​. The firm's co-founders, Gurdane Bhutani and Zeshan Muhammedi, lead a team that provides hands-on support to portfolio companies, leveraging their expertise and extensive network to drive growth and innovation​​. MBX Capital's strategic approach and active involvement make it a key player in the venture capital landscape for healthcare and life sciences startups.

MD Start is a unique medtech incubator and fund based in Paris, dedicated to transforming early-stage medical device ideas into commercially viable companies. Founded in 2010, it partners with leading institutions like Medtronic, Bpifrance, and Sofinnova Partners to support innovative concepts that are too early for traditional venture investment. MD Start’s approach is hands-on, focusing on developing, managing, and de-risking projects to attract later-stage investment. The incubator primarily targets groundbreaking European medtech innovations, working closely with physicians and researchers to evaluate over 1,400 ideas, resulting in the creation of 7 companies. With expertise spanning product development, regulatory strategy, and clinical validation, MD Start ensures rapid and capital-efficient progress from idea to market. The team is led by experienced industry veterans like Gérard Hascoët, Anne Osdoit, and Lukas Guenther, who are instrumental in the incubator's success. Their focus is on turning early concepts into disruptive technologies, particularly in therapeutic devices and surgical tools. MD Start’s unique model and strong industry backing make it a vital player in Europe’s medtech landscape.